273
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Demographic and Clinical Correlates of Treatment Completion among Older Adults with Heroin and Prescription Opioid Use Disorders

, PhDORCID Icon, , PhD, , PhD & , MD, MPH
Pages 440-451 | Received 30 Apr 2021, Accepted 07 Sep 2021, Published online: 25 Nov 2021

References

  • Bazargan-Hejazi, S., V. De Lucia, D. Pan, M. Mojtahedzadeh, E. Rahmani, S. Jabori, G. Zahmatkesh, and M. Bazargan. 2016. Gender comparison in referrals and treatment completion to residential and outpatient alcohol treatment. Substance Abuse: Research and Treatment 10:109–16. doi:10.4137/SART.S39943.
  • Bell, J., and J. Strang. 2020. Medication treatment of opioid use disorder. Biological Psychiatry 87 (1):82–88. doi:10.1016/j.biopsych.2019.06.020.
  • Bobashev, G., K. Tebbe, N. Peiper, and L. Hoffer. 2018. Polydrug use among heroin users in Cleveland, OH. Drug and Alcohol Dependence 192:80–87. doi:10.1016/j.drugalcdep.2018.06.039.
  • Bohnert, A. S. B., G. P. Guy Jr, and J. L. Losby. 2018. Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention’s 2016 Opioid Guideline. Annals of Internal Medicine 169 (6):367–75. doi:10.7326/M18-1243.
  • Carew, A. M., and C. Comiskey. 2018. Treatment for opioid use and outcomes in older adults: A systematic literature review. Drug and Alcohol Dependence 182:48–57. doi:10.1016/j.drugalcdep.2017.10.007.
  • Carter, M. W., B. K. Yang, M. Davenport, and A. Kabel. 2019. Increasing rates of opioid misuse among older adults visiting emergency departments. Innovation in Aging 3 (1):igz002. doi:10.1093/geroni/igz002.
  • Centers for Disease Control and Prevention. 2019. 2018 annual surveillance report of drug-related risk and outcomes. https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf.
  • Centers for Disease Control and Prevention. 2020. U.S. opioid dispensing rate maps. https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html.
  • Choi, N. G., and D. M. DiNitto. 2020. Older-adult marijuana users in substance use treatment: Characteristics associated with treatment completion. Journal of Psychoactive Drugs 52 (3):218–27. doi:10.1080/02791072.2020.1745966.
  • Choi, N. G., and D. M. DiNitto. 2021b. Characteristics of mental health and substance use service facilities for older adults: Findings from national surveys. Clinical Gerontologist. doi:10.1080/07317115.2020.1862381.
  • Choi, N. G., D. M. DiNitto, and B. Y. Choi. 2021a. Prescription pain reliever use and misuse among cannabis users aged 50+. Clinical Gerontologist 44 (1):53–65. doi:10.1080/07317115.2020.1757540.
  • Coffa, D., and H. Snyder. 2019. Opioid use disorder: Medical treatment options. American Family Physician 100 (7):416–25.
  • Cotton, B. P., W. C. Bryson, and M. L. Bruce. 2018. Methadone maintenance treatment for older adults: Cost and logistical considerations. Psychiatric Services 69 (3):338–40. doi:10.1176/appi.ps.201700137.
  • Dahlhamer, J., J. Lucas, C. Zelaya, R. Nahin, S. Mackey, L. DeBar, R. Kerns, M. Von Korff, L. Porter, and C. Helmick. 2018. Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR Morbidity and Mortality Weekly Report 67 (36):1001–06. doi:10.15585/mmwr.mm6736a2.
  • Domenichiello, A. F., and C. E. Ramsden. 2019. The silent epidemic of chronic pain in older adults. Progress in Neuropsychopharmacololy & Biological Psychiatry 93:284–90. doi:10.1016/j.pnpbp.2019.04.006.
  • Dong, H., K. Hayashi, M. J. Milloy, K. DeBeck, J. Singer, H. Wong, E. Wood, and T. Kerr. 2020. Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting. Drug and Alcohol Dependence 212:108005. doi:10.1016/j.drugalcdep.2020.108005.
  • Dowell, D., T. M. Haegerich, and R. Chou. 2016. CDC guideline for prescribing opioids for chronic pain - United States, 2016: Recommendations and report. MMWR Morbidity and Mortality Weekly Report 65 (1):1–49. Erratum in: MMWR Recomm Rep. 2016, 65 (11),295. doi:10.15585/mmwr.rr6501e1.
  • Huhn, A. S., J. G. Hobelmann, J. C. Strickland, G. A. Oyler, C. L. Bergeria, A. Umbricht, and K. E. Dunn. 2020. Differences in availability and use of medications for opioid use disorder in residential treatment settings in the United States. JAMA Network Open 3 (2):e1920843. doi:10.1001/jamanetworkopen.2019.2084.
  • Huhn, A. S., E. C. Strain, D. A. Tompkins, and K. E. Dunn. 2018. A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder. Drug and Alcohol Dependence 193:142–47. doi:10.1016/j.drugalcdep.2018.10.002.
  • Ibabe, I., J. A. Stein, A. Nyamathi, and P. M. Bentler. 2014. Predictors of substance abuse treatment participation among homeless adults. Journal of Substance Abuse Treatment 46 (3):374–81. doi:10.1016/j.jsat.2013.10.008.
  • Lynch, A., S. Arndt, and L. Acion. 2020. Late- and typical-onset heroin use among older adults seeking treatment for opioid use disorder. American Journal of Geriatric Psychiatry. S1064-7481(20)30572-8. doi:10.1016/j.jagp.2020.12.005.
  • Mattson, C. L., L. J. Tanz, K. Quinn, M. Kariisa, P. Patel, and N. L. Davis. 2021. Trends and geographic patterns in drug and synthetic ppioid overdose deaths - United States, 2013–2019. MMWR Morbidity and Mortality Weekly Report 70 (6):202–07. doi:10.15585/mmwr.mm7006a4.
  • Moore, K. E., W. Roberts, H. H. Reid, K. M. Z. Smith, L. M. S. Oberleitner, and S. A. McKee. 2019. Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review. Journal of Substance Abuse and Treatment 99:32–43. doi:10.1016/j.jsat.2018.12.003.
  • Morse, S. A., C. Watson, S. A. MacMaster, and B. E. Bride. 2015. Differences between older and younger adults in residential treatment for co-occurring disorders. Journal of Dual Diagnosis 11 (1):75–82. doi:10.1080/15504263.2014.993263.
  • Murthy, P., J. Mahadevan, and P. K. Chand. 2019. Treatment of substance use disorders with co-occurring severe mental health disorders. Current Opinions in Psychiatry 32 (4):293–99. doi:10.1097/YCO.0000000000000510.
  • Neighbors, C. J., S. Choi, S. Healy, R. Yerneni, T. Sun, and L. Shapoval. 2019. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York. Substance Abuse Treatment Prevention and Policy 14 (1):28. doi:10.1186/s13011-019-0215-4.
  • O’Brien, M. D. C., and A. P. F. Wand. 2020. A systematic review of the evidence for the efficacy of opioids for chronic non-cancer pain in community-dwelling older adults. Age and Ageing 49 (2):175–83. doi:10.1093/ageing/afz175.
  • Oesterle, T. S., N. J. Thusius, T. A. Rummans, and M. S. Gold. 2019. Medication-assisted treatment for opioid-use disorder. Mayo Clinic Proceedings 94 (10):2072–86. doi:10.1016/j.mayocp.2019.03.029.
  • Office of Inspector General. 2018. Opioid use in medicare part D remains concerning. https://oig.hhs.gov/oei/reports/oei-02-18-00220.pdf.
  • Olfson, M., S. Wang, M. M. Wall, and C. Blanco. 2020. Trends in opioid prescribing and self-reported pain among US adults. Health Affairs (Millwood) 39 (1):146–54. doi:10.1377/hlthaff.2019.00783.
  • Pickard, J. G., P. Sacco, C. van Den Berk-clark, and E. P. Cabrera-Nguyen. 2020. The effect of legal mandates on substance use disorder treatment completion among older adults. Aging and Mental Health 24 (3):497–503. doi:10.1080/13607863.2018.1544209.
  • Pouget, E. R., C. Fong, and A. Rosenblum. 2018. Racial/ethnic differences in prevalence trends for heroin use and non-medical use of prescription opioids among entrants to opioid treatment programs, 2005–2016. Substance Use and Misuse 53 (2):290–300. doi:10.1080/10826084.2017.1334070.
  • Schepis, T. S., J. A. Ford, L. Wastila, and S. E. McCabe. 2020. Opioid-involved prescription drug misuse and poly-prescription drug misuse in U.S. older adults. Aging and Mental Health:1–9, Online ahead of print. doi:10.1080/13607863.2020.1839859.
  • Schepis, T. S., L. Simoni-Wastila, and S. E. McCabe. 2019. Prescription opioid and benzodiazepine misuse is associated with suicidal ideation in older adults. International Journal of Geriatric Psychiatry 34 (1):122–29. doi:10.1002/gps.4999.
  • Shen, K., E. Barrette, and L. S. Dafny. 2020. Treatment of opioid use disorder among commercially insured US adults, 2008–17. Health Affairs (Millwood) 39 (6):993–1001. doi:10.1377/hlthaff.2019.01041.
  • Stahler, G. J., and J. Mennis. 2020. The effect of medications for opioid use disorder (MOUD) on residential treatment completion and retention in the US. Drug and Alcohol Dependence 212:108067. doi:10.1016/j.drugalcdep.2020.108067.
  • Stokes, A., K. M. Berry, K. Hempstead, D. J. Lundberg, and T. Neogi. 2019. Trends in prescription analgesic use among adults with musculoskeletal conditions in the United States, 1999–2016. JAMA Network Open 2 (12):e1917228. doi:10.1001/jamanetworkopen.2019.17228.
  • Substance Abuse and Mental Health Services Administration. 2020. Treatment Episode Data Set (TEDS) discharges, 2018. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  • Suntai, Z. D., L. H. Lee, and J. D. Leeper. 2020. Racial disparities in substance use treatment completion among older adults. Innovation in Aging 4 (6):igaa051. doi:10.1093/geroni/igaa051.
  • Unick, G. J., and D. Ciccarone. 2017. US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations. International Journal on Drug Policy 46:112–19. doi:10.1016/j.drugpo.2017.06.003.
  • Volkow, N., H. Benveniste, and A. T. McLellan. 2018. Use and misuse of opioids in chronic pain. Annual Review of Medicine 69 (1):451–65. doi:10.1146/annurev-med-011817-044739.
  • West, N. A., and R. C. Dart. 2016. Prescription opioid exposures and adverse outcomes among older adults. Pharmacoepidemiology and Drug Safety 25 (5):539–44. doi:10.1002/pds.3934.
  • Williams, A. R., H. Samples, S. Crystal, and M. Olfson. 2020. Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. American Journal of Psychiatry 177 (2):117–24. doi:10.1176/appi.ajp.2019.19060612.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.